Thus, while αVβ6 is clearly an appealing therapeutic target in HER2+ breast cancer, there is now a key need to assess exactly which patients might benefit from function-blocking anti-αVβ6 targeting therapeutics and which may not. This evidence concerns the gene ERBB2 and breast carcinoma.